Virica Biotech is one of three local life sciences organizations that received funding earlier this week from the Federal Economic Development Agency for Southern Ontario.
Already an Insider? Log in
Get Instant Access to This Article
Become an Ottawa Business Journal Insider and get immediate access to all of our Insider-only content and much more.
- Critical Ottawa business news and analysis updated daily.
- Immediate access to all Insider-only content on our website.
- 4 issues per year of the Ottawa Business Journal magazine.
- Special bonus issues like the Ottawa Book of Lists.
- Discounted registration for OBJ’s in-person events.
Click here to purchase a paywall bypass link for this article.
An Ottawa biotechnology startup says it expects to nearly double its head count over the next few years in response to growing demand for its products that help deliver groundbreaking therapies for cancer and other diseases.
Virica Biotech is one of three local life sciences organizations that received funding earlier this week from the Federal Economic Development Agency for Southern Ontario.
The six-year-old firm secured a $1.5-million interest-free loan from the federal agency to help it manufacture its state-of-the-art cell enhancers that optimize specially modified viruses called viral vectors.
Viral vectors deliver new genes that are designed to repair defective genes responsible for diseases such as cancer and muscular dystrophy as well as conditions such as hereditary blindness.
Virica, which closed a multimillion-dollar funding round in the fall of 2021, is now in the midst of another major fundraising drive as it ramps up manufacturing.
“These are exciting times,” said founder and CEO Jean-Simon Diallo, noting that the company is about to roll out a new set of gene therapy technologies.
“This funding comes at a good time to accelerate that and actually deliver that to our customers,” Diallo said of Virica’s latest innovations, which are being developed in its new lab at Carleton University.
Founded in 2018, Virica operated out of a small facility at the University of Ottawa Heart Institute from 2021 until earlier this year.
Diallo spent more than a year trying to find an R&D space in Ottawa big enough to accommodate his growing staff of more than 30 before finally securing a 4,000-square-foot lab in Carleton’s state-of-the-art Health Sciences Building.
The new research and manufacturing hub is “much newer, brighter,” explained Diallo, whose firm signed a three-year, multimillion-dollar agreement with the university that will see Virica help fund ongoing research at Carleton as well as provide $15,000 in annual funding for scholarships to support students from groups that have traditionally been underrepresented in the sciences.
“Staff morale is up … things are just better organized. People are more efficient.”
Diallo said the company expects to hire up to 27 new employees over the next several years.
“Obviously, we’re all watching the economy and (hoping) the recovery that we’re experiencing right now keeps on its trend,” he said, adding the firm plans to expand in a “very measured way.”
